Zacks Investment Research upgraded shares of TFF Pharmaceuticals (NASDAQ:TFFP) from a hold rating to a buy rating in a research note published on Thursday, Zacks.com reports. Zacks Investment Research currently has $15.00 target price on the stock.
According to Zacks, “TFF Pharmaceuticals Inc. is an early-stage biopharmaceutical company. It is focused on the development and commercialization of inhalation products for the treatment of chronic respiratory diseases and lung conditions. TFF Pharmaceuticals Inc. is based in Austin, Texas. “
Other equities analysts have also issued reports about the stock. Roth Capital raised their price target on shares of TFF Pharmaceuticals from $15.00 to $18.00 and gave the stock a buy rating in a research report on Friday, August 14th. Maxim Group raised their price target on shares of TFF Pharmaceuticals from $12.00 to $18.00 and gave the stock a buy rating in a research report on Monday.
Shares of TFF Pharmaceuticals stock traded up $0.25 during midday trading on Thursday, hitting $13.94. The company had a trading volume of 22,843 shares, compared to its average volume of 952,980. TFF Pharmaceuticals has a 12-month low of $3.44 and a 12-month high of $14.25. The stock has a market cap of $260.47 million and a price-to-earnings ratio of -4.42. The company has a fifty day simple moving average of $8.05 and a 200 day simple moving average of $5.67.
TFF Pharmaceuticals (NASDAQ:TFFP) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. As a group, sell-side analysts anticipate that TFF Pharmaceuticals will post -0.81 earnings per share for the current fiscal year.
In other news, Director Aaron G.L. Fletcher acquired 20,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were acquired at an average price of $5.08 per share, with a total value of $101,600.00. Following the purchase, the director now directly owns 95,000 shares of the company’s stock, valued at $482,600. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new stake in shares of TFF Pharmaceuticals during the 4th quarter worth approximately $85,000. BlackRock Inc. grew its stake in TFF Pharmaceuticals by 77.8% in the 1st quarter. BlackRock Inc. now owns 22,134 shares of the company’s stock valued at $84,000 after acquiring an additional 9,682 shares during the period. Sigma Planning Corp grew its stake in TFF Pharmaceuticals by 752.9% in the 1st quarter. Sigma Planning Corp now owns 89,550 shares of the company’s stock valued at $344,000 after acquiring an additional 79,050 shares during the period. Gagnon Securities LLC acquired a new stake in TFF Pharmaceuticals in the 2nd quarter valued at $1,268,000. Finally, Nantahala Capital Management LLC grew its stake in TFF Pharmaceuticals by 47.9% in the 2nd quarter. Nantahala Capital Management LLC now owns 856,517 shares of the company’s stock valued at $4,934,000 after acquiring an additional 277,300 shares during the period. 5.68% of the stock is currently owned by institutional investors and hedge funds.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc, an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
Read More: What is the definition of a trade war?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.